Lakefront Biotherapeutics NV
LKFTHealthcareNASDAQBiotechnology · Last scanned Sep 9, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Lakefront Biotherapeutics NV focuses on Biotechnology services and products. Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. At a $1.81B market cap, Lakefront Biotherapeutics NV ranks as a small-cap company within healthcare. The company's pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.
Market Cap
$1.81B
Beta
0.12
P/E (TTM)
2.64
P/E (Fwd)
-19.94
EPS (TTM)
$10.45
EPS (Fwd)
$-1.39
ROE
20.1%
ROA
9.9%
Cash
$2.24B
Total Debt
$6.4M
Free CF
$138.2M
52W Change
-11.9%
Annual Financials
Cash vs Debt
Where LKFT stands vs its 150-day and 200-day moving averages
As of the August 26, 2026 close, LKFT finished 0.90% below its 150-day moving average ($29.97) and 2.62% below its 200-day moving average ($30.50). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LKFT overbought or oversold?
At the August 26, 2026 close, LKFT's RSI(14) was 71.0, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $2.24B in cash comfortably exceeding the $6.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $138.2M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 20.1%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 9.9% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $241.2M (2022) to $1.11B (2025), reflecting a 361% increase over the period.
LKFT's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LKFT.